Journal of Neuro-Oncology

, Volume 77, Issue 3, pp 225–232 | Cite as

Lactacystin Exhibits Potent Anti-tumor Activity in an Animal Model of Malignant Glioma when Administered via Controlled-release Polymers

  • Federico G. Legnani
  • Gustavo Pradilla
  • Quoc-Anh Thai
  • Alessandro Fiorindi
  • Pablo F. Recinos
  • Betty M. Tyler
  • Sergio M. Gaini
  • Francesco DiMeco
  • Henry Brem
  • Alessandro Olivi
Laboratory Investigation

Summary

Lactacystin, a proteasome-inhibitor, has been shown to induce apoptosis of experimental gliomas in vitro. However, its systemic toxicity prevents further clinical use. To circumvent this problem, lactacystin can be delivered intratumorally. We tested the efficacy of lactacystin incorporated into controlled-release polymers for treating experimental gliomas. 9L-gliosarcoma and F98-glioma cell lines were treated with lactacystin (10–100 μg/ml) for 72 h in vitro. Cell-viability was measured with MTT-assays. Toxicity of lactacystin/polycarboxyphenoxypropane-sebacic-acid (pCPP : SA) polymers was tested in vivo using Fischer-344 rats intracranially implanted with lactacystin polymers loaded from 0.1 to 2% lactacystin by weight. The efficacy of 1, 1.3, 1.5 and 1.7% lactacystin/pCPP : SA polymers was determined in Fischer-344 rats intracranially challenged with 9L and treated either simultaneously or 5 days after tumor implantation. Lactacystin was cytotoxic in 9L cells, causing a 16 ± 8% growth inhibition at 10-μg/ml that increased to 78 ± 4% at 100-μg/ml. Similarly, lactacystin inhibited growth of F98 by 18 ± 8% at 10-μg/ml and 74 ± 2% at 100-μg/ml in vitro. Polymers released lactacystin for 21 days and intracranial implantation in rats neither generate local nor systemic toxicity at doses lower than 2%. Treatment with lactacystin/pCPP : SA polymers with loading concentrations of 1.0, 1.3, and 1.5% prolonged survival of animals intracranially challenged with 9L when polymers where inserted in the day of tumor implantation. In conclusion, lactacystin exhibits potent cytotoxic-activity against 9L and F98 in vitro, it can be efficiently incorporated and delivered using controlled-release polymers, and at the proposed concentrations lactacystin polymers are safe for CNS delivery and prolong survival in the 9L model.

Keywords

animal model brain tumor controlled-release gliomas lactacystin local delivery polymer proteasome inhibitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ and Schreiber SL (1995). Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268: 726–731PubMedCrossRefGoogle Scholar
  2. 2.
    King RW, Deshaies RJ, Peters JM and Kirschner MW (1996). How proteolysis drives the cell cycle. Science 274: 1652–1659PubMedCrossRefGoogle Scholar
  3. 3.
    An B, Goldfarb RH, Siman R and Dou QP (1998). Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5: 1062–1075PubMedCrossRefGoogle Scholar
  4. 4.
    Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H and Delic J (2000). Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 96: 269–274PubMedGoogle Scholar
  5. 5.
    Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M and Dang CV (1998). Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res 58: 4342–4348PubMedGoogle Scholar
  6. 6.
    Cusak JC Jr., Liu R, Houston M, Abendroth K, Elliott PJ and Adams J et al. (2001). Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61: 3535–3540PubMedGoogle Scholar
  7. 7.
    Russo SM, Tepper JE, Baldwin AS Jr., Liu R, Adams J and Elliott P, et al. (2001). Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183–193PubMedCrossRefGoogle Scholar
  8. 8.
    Tani E, Kitagawa H, Ikemoto H and Matsumoto T (2001). Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells. FEBS Lett 504: 53–58PubMedCrossRefGoogle Scholar
  9. 9.
    Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J and Elliott PJ, et al. (2002). A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res 8: 2505–2511PubMedGoogle Scholar
  10. 10.
    Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS and Stahl S, et al. (2002). Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420–4427PubMedCrossRefGoogle Scholar
  11. 11.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S and Irwin D, et al. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609–2617PubMedCrossRefGoogle Scholar
  12. 12.
    Lenz HJ (2003). Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl. 1): 41–48PubMedCrossRefGoogle Scholar
  13. 13.
    Legnani FG, Pradilla G, Wang PP, Brem H, Olivi A and Di Meco F (2003). Local delivery of antineoplastic agents using biodegradable polymers for the treatment of malignant brain tumors. Expert Rev Neurotherapeutics 3: 89–102CrossRefGoogle Scholar
  14. 14.
    Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63PubMedCrossRefGoogle Scholar
  15. 15.
    Sampath P, Amundson E, Wall ME, Tyler BM, Wani MC and Alderson LM, et al. (2003). Camptothecin analogs in malignant gliomas: comparative analysis and characterization. J Neurosurg 98: 570–577PubMedCrossRefGoogle Scholar
  16. 16.
    Adams J (2004). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360 PubMedCrossRefGoogle Scholar
  17. 17.
    DeMartino GN and Slaughter CA (1999). The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 274: 22123–22126PubMedCrossRefGoogle Scholar
  18. 18.
    Spataro V, Norbury C and Harris AL (1998). The ubiquitin–proteasome pathway in cancer. Br J Cancer 77: 448–455PubMedGoogle Scholar
  19. 19.
    Adams J (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417–421PubMedCrossRefGoogle Scholar
  20. 20.
    Adams J (2003). The proteasome: structure, function and role in the cell. Cancer Treat Rev 29(Suppl. 1): 3–9PubMedCrossRefGoogle Scholar
  21. 21.
    Karin M, Cao Y, Greten FR and Li ZW (2002). NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301–310PubMedCrossRefGoogle Scholar
  22. 22.
    Li B and Dou QP (2000). Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97: 3850–3855PubMedCrossRefGoogle Scholar
  23. 23.
    Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Brock M, Kim KB, et al. (2000). The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol 164: 6147–6157PubMedGoogle Scholar
  24. 24.
    Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G and Goldberg AL, et al. (1997). Lactacystin and clasto-lactacystin beta- lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272: 13437–13445PubMedCrossRefGoogle Scholar
  25. 25.
    Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA and Melandri FD, et al. (1997). Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272: 182–188PubMedCrossRefGoogle Scholar
  26. 26.
    Fenteany G, Standaert RF, Reichard GA, Corey EJ and Schreiber SL (1994). A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci USA 91: 3358–3362PubMedCrossRefGoogle Scholar
  27. 27.
    Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH and Liu LF (2001). Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61: 5926–5932PubMedGoogle Scholar
  28. 28.
    Ogiso Y, Tomida A, Lei S, Omura S and Tsuruo T (2000). Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 60: 2429–2434PubMedGoogle Scholar
  29. 29.
    Drexler HC, Risau W and Konerding MA (2000). Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. Faseb J 14: 65–77PubMedGoogle Scholar
  30. 30.
    Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC and Sisti M (1995). The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 26: 111–123 PubMedCrossRefGoogle Scholar
  31. 31.
    Brem H, Piantadosi S, Burger PC, Walker M, Selker R and Vick NA (1995). Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345: 1008–1012PubMedCrossRefGoogle Scholar
  32. 32.
    Olivi A, Grossman SA, Tatter S, Barker F, Judy K and Olsen J, et al. (2003). Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 21: 1845–1849PubMedCrossRefGoogle Scholar
  33. 33.
    Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41: 44–48; discussion 48–49, 1997Google Scholar
  34. 34.
    Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R and Warnke PC, et al. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5: 79–88PubMedCrossRefGoogle Scholar
  35. 35.
    Lenz HJ: Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29 (Suppl. 1): 41–48, 2003Google Scholar
  36. 36.
    Richardson P ( 2003). Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 29(Suppl. 1): 33–39PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Federico G. Legnani
    • 1
    • 3
  • Gustavo Pradilla
    • 1
    • 2
  • Quoc-Anh Thai
    • 1
  • Alessandro Fiorindi
    • 5
  • Pablo F. Recinos
    • 1
  • Betty M. Tyler
    • 1
  • Sergio M. Gaini
    • 3
  • Francesco DiMeco
    • 1
    • 4
  • Henry Brem
    • 1
    • 2
  • Alessandro Olivi
    • 1
    • 2
  1. 1.Department of Neurosurgery, School of MedicineJohns Hopkins UniversityItaly
  2. 2.Department of Oncology, School of MedicineJohns Hopkins UniversityItaly
  3. 3.Department of Neurosurgery, School of MedicineUniversity of MilanItaly
  4. 4.Istituto Nazionale Neurologico “Carlo Besta”MilanItaly
  5. 5.Department of NeurosurgeryOspedale Ca’ FoncelloTrevisoItaly

Personalised recommendations